How have JAGX shares performed in 2023?

Jaguar Health's stock was trading at $0.0869 on January 1st, 2023. Since then, JAGX shares have increased by 272.8% and is now trading at $0.3240. View the best growth stocks for 2023 here .

Are investors shorting Jaguar Health?

Jaguar Health saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 827,900 shares, a decrease of 26.1% from the October 31st total of 1,120,000 shares. Based on an average daily trading volume, of 4,860,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.3% of the company's stock are short sold. View Jaguar Health's Short Interest .

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our JAGX earnings forecast .

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) posted its quarterly earnings results on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company earned $0.63 million during the quarter. Jaguar Health had a negative net margin of 370.40% and a negative trailing twelve-month return on equity of 1,191.67%. During the same quarter in the previous year, the company posted ($0.63) earnings per share.

When did Jaguar Health's stock split?

Jaguar Health shares reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , Vaxart (VXRT) , Purple Biotech (KTOV) , Onconova Therapeutics (ONTX) , Tonix Pharmaceuticals (TNXP) , Biopharmx (BPMX) , Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT) .

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX)

$0.32

-0.07 (-17.77%)

(As of 12/5/2023 ET)

Compare

Today's Range: $0.31
▼
$0.38
50-Day Range: $0.23
▼
$0.46
52-Week Range: $0.21
▼
$9.53

Volume: 7.83 million shs
Average Volume: 2.72 million shs
Market Capitalization: $16.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Jaguar Health MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.83) to ($0.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

896th out of 948 stocks

Pharmaceutical Preparations Industry

406th out of 423 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Jaguar Health.

5.0

Short Interest

Percentage of Shares Shorted
2.27% of the float of Jaguar Health has been sold short.
Short Interest Ratio / Days to Cover
Jaguar Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Jaguar Health has recently decreased by 26.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Jaguar Health does not currently pay a dividend.
Dividend Growth
Jaguar Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JAGX.

2.0

News and Social Media Coverage

News Sentiment
Jaguar Health has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Jaguar Health this week, compared to 2 articles on an average week.
Search Interest
Only 10 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jaguar Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.16% of the stock of Jaguar Health is held by insiders.
Percentage Held by Institutions
Only 12.24% of the stock of Jaguar Health is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Jaguar Health are expected to grow in the coming year, from ($5.83) to ($0.40) per share.

See Top Rated MarketRank™ Stocks Here

About Jaguar Health Stock (NASDAQ:JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

JAGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JAGX Stock News Headlines

December 4, 2023 | msn.com

FDA renews conditional approval for Jaguar canine chemo drug

December 4, 2023 | finance.yahoo.com

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 1, 2023 | americanbankingnews.com

Jaguar Health (NASDAQ:JAGX) Coverage Initiated by Analysts at StockNews.com

November 30, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference

November 30, 2023 | finance.yahoo.com

Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference

November 22, 2023 | msn.com

Jaguar Health falls after update on Phase 3 trial for plant-based drug

November 21, 2023 | msn.com

Jaguar Health’s stock drops after results supporting ‘paramount’ trial have not been received yet

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 21, 2023 | finance.yahoo.com

Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming

November 15, 2023 | finance.yahoo.com

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call Transcript

November 15, 2023 | finance.yahoo.com

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

November 14, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health Reports Third Quarter 2023 Financial Results

November 14, 2023 | finance.yahoo.com

Jaguar Health Reports Third Quarter 2023 Financial Results

November 13, 2023 | benzinga.com

Earnings Preview For Jaguar Health

November 9, 2023 | finance.yahoo.com

Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium

November 7, 2023 | finance.yahoo.com

REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST

November 2, 2023 | finance.yahoo.com

Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets

November 1, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

November 1, 2023 | finance.yahoo.com

Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

October 30, 2023 | finance.yahoo.com

Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet

October 26, 2023 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health to Present November 1st at Emerging Growth Conference

October 26, 2023 | finance.yahoo.com

Jaguar Health to Present November 1st at Emerging Growth Conference

October 25, 2023 | finance.yahoo.com

Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th at the San Antonio Breast Cancer Symposium

October 23, 2023 | finance.yahoo.com

Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications

October 19, 2023 | finance.yahoo.com

Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease

October 18, 2023 | finance.yahoo.com

Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug

See More Headlines

Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/17/2021
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JAGX
CUSIP: N/A
CIK: 1585608
Web: www.jaguaranimalhealth.com
Phone: (415) 371-8300
Fax: N/A
Employees: 60
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,450,000.00
Net Margins: -370.40%
Pretax Margin: -380.79%
Return on Equity: -1,191.67%
Return on Assets: -79.95%

Debt

Debt-to-Equity Ratio: 22.00
Current Ratio: 1.77
Quick Ratio: 1.10

Sales & Book Value

Annual Sales: $11.96 million
Price / Sales: 1.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.32) per share
Price / Book: -1.05

Miscellaneous

Outstanding Shares: 50,760,000
Free Float: 50,675,000
Market Cap: $17.11 million
Optionable: Not Optionable
Beta: 1.68

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Lisa A. Conte (Age 64)
Founder, CEO, President & Director
Comp: $771.4k
Dr. Pravin R. Chaturvedi Ph.D. (Age 60)
Chief Scientific Officer & Chair of Scientific Advisory Board
Comp: $539.04k
Mr. Jonathan S. Wolin CPA (Age 60)
J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel
Comp: $520.29k
Mr. Ian H. Wendt M.B.A. (Age 55)
Chief Commercial Officer
Comp: $441.31k
Dr. Steven R. King Ph.D. (Age 65)
Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
Comp: $477.66k
Ms. Carol R. Lizak M.B.A. (Age 59)
Chief Financial Officer
Mr. Peter Hodge
Senior Director of Investor Relations, Business Development & Special Events
Dr. Karen J. Brunke Ph.D. (Age 71)
Executive VP of Corporate & Business Development
Mr. David Sesin
Chief Manufacturing Officer

Key Competitors

View All Competitors

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed in 2023?: Jaguar Health's stock was trading at $0.0869 on January 1st, 2023. Since then, JAGX shares have increased by 272.8% and is now trading at $0.3240.
View the best growth stocks for 2023 here.
Are investors shorting Jaguar Health?: Jaguar Health saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 827,900 shares, a decrease of 26.1% from the October 31st total of 1,120,000 shares. Based on an average daily trading volume, of 4,860,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.3% of the company's stock are short sold.
View Jaguar Health's Short Interest.
When is Jaguar Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our JAGX earnings forecast.
How were Jaguar Health's earnings last quarter?: Jaguar Health, Inc. (NASDAQ:JAGX) posted its quarterly earnings results on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company earned $0.63 million during the quarter. Jaguar Health had a negative net margin of 370.40% and a negative trailing twelve-month return on equity of 1,191.67%. During the same quarter in the previous year, the company posted ($0.63) earnings per share.
When did Jaguar Health's stock split?: Jaguar Health shares reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).
When did Jaguar Health IPO?: (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
Who are Jaguar Health's major shareholders?: Jaguar Health's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Jaguar Health?: Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:JAGX) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX)

Jaguar Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows